Myhibbin is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 5 US drug patents filed from 2024 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 16, 2039. Details of Myhibbin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12226526 | Mycophenolate oral suspension |
Aug, 2039
(12 years from now) | Active |
| US12097285 | Mycophenolate oral suspension |
Aug, 2039
(12 years from now) | Active |
| US12194143 | Mycophenolate oral suspension |
Aug, 2039
(12 years from now) | Active |
| US11931455 | Pharmaceutical suspension for oral dosage |
Aug, 2039
(12 years from now) | Active |
| US12097284 | Mycophenolate oral suspension |
Aug, 2039
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Myhibbin's patents.
Latest Legal Activities on Myhibbin's Patents
Given below is the list of recent legal activities going on the following patents of Myhibbin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 18 Feb, 2025 | US12226526 |
| Email Notification | 18 Feb, 2025 | US12226526 |
| Patent eGrant Notification | 18 Feb, 2025 | US12226526 |
| Recordation of Patent eGrant | 18 Feb, 2025 | US12226526 |
| Patent Issue Date Used in PTA Calculation | 18 Feb, 2025 | US12226526 |
| Recordation of Patent Grant Mailed | 18 Feb, 2025 | US12226526 |
| Email Notification | 29 Jan, 2025 | US12226526 |
| Issue Notification Mailed | 29 Jan, 2025 | US12226526 |
| Patent Issue Date Used in PTA Calculation | 14 Jan, 2025 | US12194143 |
| Recordation of Patent eGrant | 14 Jan, 2025 | US12194143 |
US patents provide insights into the exclusivity only within the United States, but
Myhibbin is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Myhibbin's family patents as well as insights into
ongoing legal events
on those patents.
Myhibbin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Myhibbin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Myhibbin's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 16, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Myhibbin Generic API suppliers:
Mycophenolate Mofetil is the generic name for the brand Myhibbin. 24 different companies have already filed for the generic of Myhibbin, with Alkem Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Myhibbin's generic
Alternative Brands for Myhibbin
There are several other brand drugs in the same treatment category and using the same active ingredient (Mycophenolate Mofetil) as Myhibbin. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Veloxis Pharms Inc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Mycophenolate Mofetil. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Roche Palo |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Mycophenolate Mofetil, Myhibbin's active ingredient. Check the complete list of approved generic manufacturers for Myhibbin
About Myhibbin
Myhibbin is a drug owned by Azurity Pharmaceuticals Inc. Myhibbin uses Mycophenolate Mofetil as an active ingredient. Myhibbin was launched by Azurity in 2024.
Approval Date:
Myhibbin was approved by FDA for market use on 01 May, 2024.
Active Ingredient:
Myhibbin uses Mycophenolate Mofetil as the active ingredient. Check out other Drugs and Companies using Mycophenolate Mofetil ingredient
Dosage:
Myhibbin is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG/ML | SUSPENSION | Prescription | ORAL |